Olivia McCarthy1, Rachel Deere2, Max L Eckstein3,4, Jason Pitt1, Ben Wellman1, Stephen C Bain5, Othmar Moser3,4, Richard M Bracken1. 1. Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, Swansea, United Kingdom. 2. Department for Health, University of Bath, Bath, United Kingdom. 3. Division of Exercise Physiology and Metabolism, Department of Sport Science, University of Bayreuth, Bayreuth, Germany. 4. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 5. Diabetes Research Group, Medical School, Swansea University, Swansea, United Kingdom.
Abstract
Aim: To explore the influence of clinical exercise trial participation on glycaemia and insulin therapy use in adults with type 1 diabetes (T1D). Research Design and Methods: This study involved a secondary analysis of data collected from 16 individuals with T1D who completed a randomized clinical trial consisting of 23-h in-patient phases with a45-min evening bout of moderate intensity continuous exercise. Participants were switched from their usual basal-bolus therapy to ultra-long acting insulin degludec and rapid-acting insulin aspart as well as provided with unblinded interstitial flash-glucose monitoring systems. To assess the impact of clinical trial participation, weekly data obtained at the screening visit (pre-study involvement) were compared against those collated on the last experimental visit (post-study involvement). Interstitial glucose [iG] data were split into distinct glycaemic ranges and stratified into day (06:00-23:59) and night (00:00-05:59) time periods. A p-value of ≤ 0.05 was accepted for significance. Results: Following study completion, there were significant decreases in both the mean nocturnal iG concentration (Δ-0.9 ± 4.5 mmol.L-1, p < 0.001) and the time spent in severe hyperglycaemia (Δ-7.2 ± 9.8%, p = 0.028) during the night-time period. The total daily (Δ-7.3 ± 8.4 IU, p = 0.003) and basal only (Δ-2.3 ± 3.8 IU, p = 0.033) insulin dose requirements were reduced over the course of study involvement. Conclusions: Participation in clinical research may foster improved nocturnal glycaemia and reduced insulin therapy use in people with T1D. Recognition of these outcomes may help encourage volunteers to partake in clinical research opportunities for improved diabetes-related health outcomes. Clinical Trial Registration: DRKS.de; DRKS00013509.
RCT Entities:
Aim: To explore the influence of clinical exercise trial participation on glycaemia and insulin therapy use in adults with type 1 diabetes (T1D). Research Design and Methods: This study involved a secondary analysis of data collected from 16 individuals with T1D who completed a randomized clinical trial consisting of 23-h in-patient phases with a 45-min evening bout of moderate intensity continuous exercise. Participants were switched from their usual basal-bolus therapy to ultra-long acting insulin degludec and rapid-acting insulin aspart as well as provided with unblinded interstitial flash-glucose monitoring systems. To assess the impact of clinical trial participation, weekly data obtained at the screening visit (pre-study involvement) were compared against those collated on the last experimental visit (post-study involvement). Interstitial glucose [iG] data were split into distinct glycaemic ranges and stratified into day (06:00-23:59) and night (00:00-05:59) time periods. A p-value of ≤ 0.05 was accepted for significance. Results: Following study completion, there were significant decreases in both the mean nocturnal iG concentration (Δ-0.9 ± 4.5 mmol.L-1, p < 0.001) and the time spent in severe hyperglycaemia (Δ-7.2 ± 9.8%, p = 0.028) during the night-time period. The total daily (Δ-7.3 ± 8.4 IU, p = 0.003) and basal only (Δ-2.3 ± 3.8 IU, p = 0.033) insulin dose requirements were reduced over the course of study involvement. Conclusions: Participation in clinical research may foster improved nocturnal glycaemia and reduced insulin therapy use in people with T1D. Recognition of these outcomes may help encourage volunteers to partake in clinical research opportunities for improved diabetes-related health outcomes. Clinical Trial Registration: DRKS.de; DRKS00013509.
Authors: Sheri R Colberg; Ronald J Sigal; Jane E Yardley; Michael C Riddell; David W Dunstan; Paddy C Dempsey; Edward S Horton; Kristin Castorino; Deborah F Tate Journal: Diabetes Care Date: 2016-11 Impact factor: 19.112
Authors: Barbara Bohn; Antje Herbst; Martin Pfeifer; Dietmar Krakow; Stefan Zimny; Florian Kopp; Andreas Melmer; Jürgen M Steinacker; Reinhard W Holl Journal: Diabetes Care Date: 2015-05-26 Impact factor: 19.112
Authors: Richard M Bergenstal; Andrew J Ahmann; Timothy Bailey; Roy W Beck; Joan Bissen; Bruce Buckingham; Larry Deeb; Robert H Dolin; Satish K Garg; Robin Goland; Irl B Hirsch; David C Klonoff; Davida F Kruger; Glenn Matfin; Roger S Mazze; Beth A Olson; Christopher Parkin; Anne Peters; Margaret A Powers; Henry Rodriguez; Phil Southerland; Ellie S Strock; William Tamborlane; David M Wesley Journal: Diabetes Technol Ther Date: 2013-02-28 Impact factor: 6.118